Science Explorer Back to mapMap
Discussion
Institution · SynZyme Technologies (United States)

Most cited papers from SynZyme Technologies (United States)

SynZyme Technologies (United States)

What are the most cited papers from SynZyme Technologies (United States)?

The most cited paper from SynZyme Technologies (United States) is "Production of goats by somatic cell nuclear transfer" (Alexander B. Baguisi, Esmail Behboodi, David T. Melican et al., 1999), with 1,005 citations. Next come "LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase" (538) and "Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance" (538).

Showing 50 of 60 papers. Every paper with more than 67 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Production of goats by somatic cell nuclear transfer Alexander B. Baguisi, Esmail Behboodi, David T. Melican et al. · Nature Biotechnology May 1999 1,005
2 LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase David Reczek, Michael Schwake, J Oltmann Schröder et al. · Cell Open access Nov 2007 538
3 Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance Masaki Terabe, So Matsui, Jong-Myun Park et al. · The Journal of Experimental Medicine Open access Dec 2003 538
4 Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy Beth L. Thurberg, Helmut G. Rennke, Robert B. Colvin et al. · Kidney International Open access Dec 2002 335
5 CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy S. Pablo Sardi, Jennifer Leigh Clarke, Cathrine Kinnecom et al. · Proceedings of the National Academy of Sciences Open access 5 Jul 2011 324
6 Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry Robert James Hopkin, John J. Bissler, Maryam Banikazemi et al. · Pediatric Research 9 Oct 2008 306
7 CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy Marco A. Passini, Jie Bu, Eric M. Roskelley et al. · Journal of Clinical Investigation Open access 16 Mar 2010 298
8 Discovery and development of clofarabine: a nucleoside analogue for treating cancer Peter L. Bonate, Larry E. Arthaud, William R. Jr. Cantrell et al. · Nature Reviews Drug Discovery Review Oct 2006 264
9 Exploring the Specificity of Nanozymes Huizhen Fan, Ruofei Zhang, Kelong Fan et al. · ACS Nano 12 Jan 2024 261
10 The phosphatonin pathway: New insights in phosphate homeostasis Susan C. Schiavi, Rajiv Kumar · Kidney International Open access 16 Dec 2003 253
11 Reduced Inflammatory Response to Plasmid DNA Vectors by Elimination and Inhibition of Immunostimulatory CpG Motifs Nelson S. Yew, Hongmei Zhao, I‐Huan Wu et al. · Molecular Therapy Open access Mar 2000 224
12 CpG-Depleted Plasmid DNA Vectors with Enhanced Safety and Long-Term Gene Expression in Vivo Nelson S. Yew, Hongmei Zhao, Malgorzata Przybylska et al. · Molecular Therapy Open access Jun 2002 223
13 Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism Suzanne M. Jan de Beur, Richard B. Finnegan, John Vassiliadis et al. · Journal of Bone and Mineral Research Jun 2002 217
14 Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens Johanne M Kaplan, Queendy Yu, Susan Piraino et al. · The Journal of Immunology Jul 1999 206
15 Collagen matrices attenuate the collagen-synthetic response of cultured fibroblasts to TGF-β Richard A.F. Clark, Larry D. Nielsen, Marshall P. Welch et al. · Journal of Cell Science Mar 1995 203
16 Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function Qun Zhou, Srinivas Shankara, Andre J Roy et al. · Biotechnology and Bioengineering 6 Aug 2007 189
17 The Temporal Effects of Anti-TGF-β1, 2, and 3 Monoclonal Antibody on Wound Healing and Hypertrophic Scar Formation Leonard Lu, Alexandrina S. Saulis, W. Robert Liu et al. · Journal of the American College of Surgeons 12 Jul 2005 177
18 Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease Yunxiang Zhu, Ji-Lei Jiang, Nathan Gumlaw et al. · Molecular Therapy Open access 10 Mar 2009 176
19 Intracranial Delivery of CLN2 Reduces Brain Pathology in a Mouse Model of Classical Late Infantile Neuronal Ceroid Lipofuscinosis Marco A. Passini, James C. Dodge, Jie Bu et al. · Journal of Neuroscience Open access Feb 2006 171
20 Transforming Growth Factor-β and the Immune Response to Malignant Disease Beverly A. Teicher · Clinical Cancer Research Nov 2007 158
21 Cardiac Microvascular Pathology in Fabry Disease Beth L. Thurberg, John T. Fallon, Richard N. Mitchell et al. · Circulation Open access 4 May 2009 155
22 Competing Risks for Death and Cardiac Transplantation in Children With Dilated Cardiomyopathy Jorge A. Alvarez, Endel John Orav, James D. Wilkinson et al. · Circulation Open access 26 Jul 2011 153
23 Cysteine proteases as targets for metal-based drugs Simon Paul Fricker · Metallomics 2010 143
24 Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study KB Sims, GM Pastores, NJ Weinreb et al. · Clinical Genetics Open access 7 Apr 2008 135
25 High and Sustained Transgene Expression in Vivo from Plasmid Vectors Containing a Hybrid Ubiquitin Promoter Nelson S. Yew, Malgorzata Przybylska, Robin J. Ziegler et al. · Molecular Therapy Open access Jul 2001 135
26 Modification of an Adenoviral Vector with Biologically Selected Peptides: A Novel Strategy for Gene Delivery to Cells of Choice Helen Romanczuk, Chad E. Galer, Joseph Zabner et al. · Human Gene Therapy 10 Nov 1999 135
27 The long-term international safety experience of imiglucerase therapy for Gaucher disease Kathryn A. Starzyk, Susan M. Richards, John D. Yee et al. · Molecular Genetics and Metabolism 2 Nov 2006 123
28 Healing of chondral and osteochondral defects in a canine model: the role of cultured chondrocytes in regeneration of articular cartilage Sonya Shortkroff, Leesa M. Barone, H.‐P. Hsu et al. · Biomaterials 1996 122
29 Prenatal diagnosis of 45,X and 45,X mosaicism: the need for thorough cytogenetic and clinical evaluations Bing Huang, Maya Thangavelu, Sucheta Bhatt et al. · Prenatal Diagnosis Feb 2002 120
30 Mechanism of cytochrome P450-3A inhibition by ketoconazole David J. Greenblatt, Yanli Zhao, Karthik Venkatakrishnan et al. · Journal of Pharmacy and Pharmacology Open access 14 Jan 2011 120
31 A modified model of graft‐versus‐host–induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease Melanie C. Ruzek, Sharda S. Jha, Steve Ledbetter et al. · Arthritis & Rheumatism Apr 2004 120
32 Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease Yan An, Sarah P. Young, Priya Sunil Kishnani et al. · Molecular Genetics and Metabolism 11 May 2005 112
33 Reduced Thrombus Formation by Hyaluronic Acid Coating of Endovascular Devices Stefan Verheye, Christos P. Markou, Mahomed Y. Salame et al. · Arteriosclerosis Thrombosis and Vascular Biology Open access Apr 2000 112
34 Recombinant Human Thyroid Stimulating Hormone: Development of a Biotechnology Product for Detection of Metastatic Lesions of Thyroid Carcinoma Edward S. Cole, Karen S. Lee, Kevin Lauziere et al. · Nature Biotechnology Sep 1993 108
35 A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease Bernard Bénichou, Sunita Goyal, Crystal Sung et al. · Molecular Genetics and Metabolism 4 Dec 2008 106
36 Activation of the Unfolded Protein Response by ΔF508 CFTR Rafał Bartoszewski, András Rab, Asta Jurkuvenaite et al. · American Journal of Respiratory Cell and Molecular Biology Open access 5 May 2008 105
37 Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 Gregory Alex Grabowski, Katherine A. Kacena, J. Alexander Cole et al. · Genetics in Medicine Open access Feb 2009 102
38 Genomic analysis of partial 21q monosomies with variable phenotypes Elisha D. O. Roberson, Elizabeth Wohler, Julie Elizabeth Hoover-Fong et al. · European Journal of Human Genetics Open access 8 Sep 2010 100
39 Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker Sarah P. Young, Haoyue Zhang, Deyanira Corzo et al. · Genetics in Medicine Open access Jul 2009 96
40 Electron Paramagnetic Resonance Imaging of Rat Heart with Nitroxide and Polynitroxyl-Albumin Periannan Kuppusamy, Penghai Wang, Jay Louis Zweier et al. · Biochemistry 1996 93
41 Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization Guido J. K. Tricot, Michele Cottler‐Fox, Gary C Calandra · Bone Marrow Transplantation 22 Jun 2009 88
42 Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and -galactosidase A activity Justina C. Wu, Carolyn Yung Ho, Hicham Skali et al. · European Heart Journal Open access 7 Jan 2010 86
43 A phase 2a, randomized, double‐blind 28‐day study of TZP‐102 a ghrelin receptor agonist for diabetic gastroparesis Niels Ejskjær, John M. Wo, Tuba Esfandyari et al. · Neurogastroenterology & Motility 23 Dec 2012 86
44 Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry Torquil Watt, Alessandro P. Burlina, Chiara Cazzorla et al. · Genetics in Medicine Open access 29 Sep 2010 85
45 Immunomodulatory Activity of Mesenchymal Stem Cells Johanne M Kaplan, Michele E. Youd, Tracey A. Lodie · Current Stem Cell Research & Therapy Dec 2011 84
46 Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis Aliza Bitton Ben‐Zacharia, Meagan Adamson, Allison N Boyd et al. · International Journal of MS Care Open access Nov 2018 83
47 CFTR mutation distribution among U.S. Hispanic and African American individuals: Evaluation in cystic fibrosis patient and carrier screening populations Elaine A. Sugarman, Elizabeth M. Rohlfs, Lawrence M. Silverman et al. · Genetics in Medicine Open access Sep 2004 83
48 The use of dried blood spot samples in the diagnosis of lysosomal storage disorders — Current status and perspectives Arnold J.J. Reuser, Frans W. Verheijen, Deeksha Sarihyan Bali et al. · Molecular Genetics and Metabolism 25 Jul 2011 83
49 Evaluation of Sepramesh Biosurgical Composite in a Rabbit Hernia Repair Model Keith E. Greenawalt, Timothy J. Butler, Eric A. Rowe et al. · Journal of Surgical Research Dec 2000 82
50 Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers Bagley · International Journal of Oncology Open access 9 Feb 2009 82

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.